Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816117 | 0.82 | L3MBTL1 (0.52) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL966592 | 0.82 | ATM (0.58) | L3MBTL1LMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL13779 | 0.81 | L3MBTL1 (0.50) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL967759 | 0.80 | ATM (0.56) | L3MBTL1LMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL2484105 | 0.78 | SMN1; SMN2 (0.38) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL9415751 | 0.77 | GLA (0.67) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL18047204 | 0.77 | TSHR (0.53) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL12888081 | 0.76 | TSHR (0.61) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL4811688 | 0.76 | GLA (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7694058 | 0.75 | GLA (0.65) | L3MBTL1TSHRPOLBGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1105376-B1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMA (JP) | 2005-02-09 | — | — | EP | claimed |
| US-6576656-B1 | Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2003-06-10 | — | — | US | claimed |
| EP-1105376-A1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-13 | — | — | EP | claimed |
| WO-2000010975-A1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2000-03-02 | — | — | WO | claimed |
| EP-2389941-A1 | Growth-hormone secretagogues | Elixir Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20080261873-A1 | Growth-Hormone Secretagogues | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1781311-A2 | GROWTH-HORMONE SECRETAGOGUES | Elixir Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006023608-A2 | GROWTH-HORMONE SECRETAGOGUES | ELIXIR PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1105376-B1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMA (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-6576656-B1 | Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261873-A1 | Growth-Hormone Secretagogues | GHSR, GHRHR, GIPR | L3MBTL1 4434/4885TSHR 93/4885POLB 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.